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Abstract: Canine transmissible venereal tumor (CTVT) is a neoplasm transmitted by the physical transfer of
viable tumor cells by direct contact with injured skin and/or mucous tissue. This review paper is aimed to
provide a compiled and enough information about cytogenic origin, immunology and morphological,
biochemical and molecular diagnosis of CTVT. These cells can transpose across histocompatibility barriers into
unrelated hosts. The progression of this tumour is unique in that, it follows a predictable growth pattern
includes progressive growth phase, stable phase and regression phase and this is followed by transplantation
immunity  in  immunocompetent  adults,  while metastasis occurs in puppies and immunosuppressed dogs.
Dogs that have recovered from CTVT have serum transferable immunity to re-infection. The etiology appears
to be cell transplant from affected to unaffected dogs. There is a remarkable aberration in the numbers and
morphology of the chromosomes of the constituent cells of CTVT. Gross findings of small nodule like lesions
which are hyperaemic the most consistent clinical finding. Smears made from the tumor reveal round cells with
vacuoles and mitotic figures. Histologically, CTVT cells exhibit radially arranged around blood and lymphatic
vessels and have a high nucleus to cytoplasm ratio with around nucleus. Most CTVT have been
immunocharacterized using several tumor markers making it easy and, antibodies against CD3, surface
immunoglobulins G and M, -light chains and -light chains are useful for differentiating CTVT from
lymphomas and plasma cell tumor. The long interspersed element (LINE) insertion near c-myc has been found
a diagnostic marker to confirm that a tumor is a CTVT. So, more study should be done on hematological and
biochemical nature of CTVT, role of the tumour stroma in the progression of CTVT and also analysis of the
temporal expression of extracellular matrix.
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INTRODUCTION Also known as Sticker´s sarcoma, this tumor was first
Cancer arises when a single cell lineage acquires by Delabere-Blaine (1928). However, it was best
somatic mutations that promote it toward a program of characterized by Sticker between the years of 1905 – 1906,
continued proliferation. Natural selection favors the most leading to its designation as Sticker Tumor for many
prolific sub clones, often steering the cancer toward a years. Sticker described this neoplasia in detail and found
more aggressive phenotype. By its nature, cancer is that it was a transmissible neoplasia predominantly
counters elective and often lethal to its host and thus localized to the genital region [3, 4].
cancer is usually an ultimately short-lived and self- This tumour is unique in oncology because it was the
destructive entity [1]. first tumour to be transmitted experimentally, this being
The canine transmissible venereal tumor (CTVT) is a achieved by the Russian veterinarian Nowinsky in 1876.
neoplasia naturally transmitted in susceptible dogs by This stimulated a lively interest among scientists and
transplantation of viable tumor cells  especially  if  there became a new starting point for the study of oncology [5].
are  abrasions  or  loss  of integrity on the surface [2]. Due to the unique nature of transmission by sexual
reported in 1820 by Hüzzard and was then later reported
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contact, naturally occurring CTVT generally develops in enabling  transposition  of  the  tissue   to  a healthy
the external genitalia [6]. Less commonly, the tumor may
also be transmitted to the nasal or oral cavities, skin and
conjunctive and the rectum by sniffing or licking [7, 8].
With genital CTVT, probably as a consequence of social
behaviors [6]. More rarely, they may be found in other
areas, including the lips, oral mucosa and peritoneum, or
in organs such as the tonsils, eye, liver, spleen, kidney,
lung and musculature [9].
Dogs of any breed, age or sex are susceptible [5].
Although dogs over  one  year  of  age  are  at  high  risk
in endemic areas, most common in dogs 2 to 5 years old
[5, 1].
The tumour is never found in virginal females and
females found to be more susceptible than males.
Naturally occurring disease may be more common in
females because one infected male often mates with
numerous females; single CTVT affected male dog spread
the disease to 11 of 12 females [5, 10, 11].
Metastasis of CTVT is uncommon, only occurring in
puppies and immunocompromised dogs. Most of the
reported metastasis cases actually are mechanical
extensions of growth or transplantation [12].
Young dogs, stray dogs and sexually active dogs are
most frequently affected by this neoplasm [5, 13]. It has a
worldwide distribution and the incidence in highest in
tropical and subtropical regions. This tumor affects dogs
(Canis familiaris) and can also infect other canids, such as
foxes, coyotes and wolves [13-15]. 
Limited reviews on diagnosis of CTVT have been
published. The aim of this paper is to review the current
knowledge of the cytogenetic feature and origin,
immunology of CTVT, morphological characteristic of
CTVT and confer its biochemical and molecular diagnosis
and to discuss how these tumour characteristics are
involved in the unique behavior of this tumour.
Etiopathogenesis of  CTVT: CTVT is usually transmitted
to genital organs during sexual intercourse but can affect
the skin via the direct implantation of tumor cells during
contact between skin and tumor masses [5, 15, 16].
CTVT transmission may be enhanced both by the
extended period of canine sexual intercourse, which
involves the mates being ‘tied’ due to the expansion of
the penis within the female genital tract and by the injuries
to the genital mucosa that are frequently incurred as
mates attempt to separate [17].
Transplantation   occurs   when intact host tumor
cells lose the expression of major histocompatibility
complex (MHC)       class        I       and        II    molecules,
animal by contact between skin and damaged mucosa
[4,16].
Study done on examining the transplantation of
CTVT cells into mice, revealed that this tumor could only
be transferred between healthy animals that shared the
same MHC or into immunocompromised recipients, as the
CTVT cells induce an immune response in healthy
recipients [4]. These studies were guided by the
transplantation theory and etiology of CTVT. The
transplantation theory is based on the observation that
experimental tumor transplantation can only occur using
living tumor cells [9]. Other studies have established that
CTVT cells can be derived following mutations induced
by viruses, chemicals or radiation of lymphohistiocytic
cells and that these clones of tumor cells can then be
disseminated by allogeneic transplantation [4].
Studies using immunohistochemical techniques
demonstrated that this neoplasm was positive for
lysozyme and alpha-1-trypsin and suggested that CTVT
is of mesenchymal and histiocytic origin [9,18, 19].
The clonal transmission of this tumor is confirmed
when studies revealed that the pattern of microsatellite
polymorphisms in CTVT from different regions of the
world showed evidence of monophyletic origin.
Mitochondrial and MHC differences suggest that many
modern CTVT clones belong to two groups distributed
around the world [4, 10].
Experimentally transferred CTVT tumors have three
distinct phases of growth, described as progressive,
stable and regressive [20, 21]. Tumors generally become
palpable 10 to 20days following experimental transfer. The
initial progressive phase, which generally lasts for a few
weeks, is characterized by a rapid increase in tumor
volume with a doubling time of between 4 and 7 days and
an estimated loss of 50% of cells [20]. During the
subsequent stable phase, there is markedly slower tumor
growth with a doubling time of approximately 20 days and
an estimated cell loss of 80 to 90% [22]. Following the
stable phase, which can last from weeks to months to
indefinitely, up to 80% of CTVT tumors enter a regressive
phase during which the tumor shrinks and eventually
disappears [20, 21]. 
The regressive phase generally lasts between 2 and
12 weeks, during which time tumors as large as 100 cm can3
disappear completely. Alternatively, rather than entering
the regressive phase, between 1 and 20% of transplanted
tumors enter a second phase of rapid growth which
progresses to metastasis [1, 20]. Spontaneous regression
of the tumor can occur, probably due to a response from
the immune system [21].
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The life history of naturally occurring CTVT is less Immunology of CTVT: Immune response against the
well understood. Although an initial progressive phase tumor plays a major role in determining the course of the
and subsequent stable phase may be observed, disease, with disease manifestation representing the
spontaneous regression has not been well documented in outcome of tumor immune evasion strategies balanced
naturally occurring CTVT [6, 22]. against host immune responses [6, 17]. 
Cytogenetic Features and Origin of CTVT: The normal infected with viable CTVT cells, disease progression and
diploid number of chromosomes in the somatic cell of the metastasis was observed; however, those dogs who
dog (Canis familiaris) is 78 and 76 of these, the autosomal quickly recovered acquired immunity against subsequent
chromosomes are acrocentric, while two, the sex implantations [22]. Conversely, dogs that have recovered
chromosomes are metacentric [4, 6]. There is a remarkable from CTVT have serum transferable immunity to re-
aberration in the numbers and morphology of the infection and puppies born to mothers that have been
chromosomes of the constituent cells of CTVT [5]. exposed to CTVT are less susceptible to the disease [17].
Cytogenetic studies on spontaneous and The frequent spontaneous regression of both natural
experimentally transplanted CTVT have been done by and experimentally transplanted CTVT associated with the
several researchers in different geographical areas of the infiltration of lymphocytes and plasma cells and with
world and these studies have demonstrated that tumours necrosis and apoptosis [15]. The transition from
from different geographical regions (France, Nigeria, progressive to regressive phases of CTVT growth is
Uganda and USA) have a similar karyotype in terms of accompanied by a marked increase in immune cell
chromosome number (59 chromosomes), the frequency of infiltration [6, 15, 22,27].
metacentric chromosomes and the incidence of marker The major histocompatibility complex (MHC) class I
chromosomes and these are clearly distinguishable from and II molecules are either not expressed or are present on
that of the normal canine cell [6, 23-25]. All dog only a small subset of neoplastic cells during the
chromosomes except X And Y are acrocentric, having progressive phase [4, 17,27]. Interestingly, a significantly
acentromere very near to the end of the chromosome, greater proportion of CTVT cells express MHC class I and
while many of the CTVT chromosomes are metacetric or II in the regression phase [17, 15]. In addition, Hsiao et al.
submetacentric, having a centromere nearer to the middle [27] showed CTVT cells can be induced to express MHC
[26]. by exposure to supernatant of cultured regressive phase
The demonstration that the karyotypes of CTVTs CTVT cells and tumor infiltrating lymphocytes, but not by
from different geographical regions are  similar  suggests progressive phase CTVT cells and tumor infiltrating
that CTVT is transferred from one animal to another by lymphocytes.
transplantation of viable cells [4, 10]. Peripheral blood lymphocytes (PBL) of dogs in which
According to Rebbeck et al. [10] the genetic ancestor CTVT had regressed, have been shown to be cytotoxic to
of CTVT was probably arose from a dog or wolf rather the tumor cells in contrast to PBL of normal dogs and
than from a distant member of the canid family. animals during progressive tumor growth [6]. Liao et al.
Furthermore, Murgia et al. [4] used microsatellite [21] showed that the  proportion  of  B  lymphocytes  in
polymorphisms to compare CTVT with normal tissues of the peripheral blood decreased dramatically with CTVT
85 breeds of dogs and eight species of wolves and found growth. The destruction of B lymphocytes  was  caused
that CTVT showed strong identity with wolves. MHC by substances released by the tumor cells, such as
variants found in the tumor cells also showed a significant cytotoxic proteins and other circulating substances.
phylogenetic relationship with wolves. These cytotoxic substances cause B lymphocyte
The research using microsatellites to determine the apoptosis during the neoplastic progression phase.
timing of the origin of CTVT indicated that CTVT Tumors are frequently infiltrated by T-lymphocytes
probably arose from a single wolf approximately 7,800 to and natural killer  (NK)  cells.  Increased  numbers of
78,000 years ago. More recently, a single clone became tumor   infiltrating    lymphocytes    (TILs),    particularly
dominant and then divided into two groups with a T-lymphocytes, are associated with tumor regression in
worldwide distribution. This study this evidence indicates CTVT [6]. The T-cell cytotoxicity is believed to be
that CTVT is the oldest transplantable somatic cell clone associated with apoptosis and apoptosis is increased in
known [10, 17]. regressing CTVTs [15].
In immunocompromised animals experimentally
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Fig. 1: Model for canine transmissible venereal tumor immune evasion. CTVT has distinct phases of growth, progressive
and regressive. During the progressive phase, the tumor cells do not express MHC class I or class II and the
tumor secretes transforming growth factor- 1 (TGF 1), a cytokine that inhibits tumor-infiltrating lymphocyte
(Including natural killer cell) cytotoxicity. Tumor cells may also inhibit some types of antigen-presenting cells.
Tumor-infiltrating lymphocytes are present in low numbers. During the regressive phase, tumor-infiltrating
lymphocytes increase in number and their secretion of IFN  and interleukin-6 (IL6) counteracts the repressive
effects of tumor-derived TGF 1 and induces MHC class I and class II expression in tumor cells. MHC expression
reveals CTVT as an allograft and it is rejected by both antibody-dependent and -independent cytotoxic
processes. Source: Murchison [17].
Hsiao et al. [28]. found that CTVT cells produce CTVT is antigenic in dogs and provokes both cell-
transforming   growth    factor    b1   (TGF 1)  and mediated and humoral immune responses. The tumor is
showed  that  this  cytokine   inhibited   NK  cell activity, able to escape immune rejection by down regulating
as  well  as  tumor  infiltrating   lymphocyte  cytotoxity. MHC, suppressing NK cells, killing B cells and preventing
The  suppressive   effects   of   TGF 1   on  NK cell the maturation of dendritic cells [17, 28, 31]. However,
killing   activity     could     be     counteracted     by   the CTVT may often eventually succumb to host defense s
pro    inflammatory      cytokine     interleukin-6   (IL6), and its final regression is accompanied by subsequent
which  is  secreted  by  tumor   infiltrating  lymphocytes immunity. Although the triumph of the immune system
[17, 28]. over CTVT may reveal an inherent weakness in the
The host derived IFN  acted synergistically with IL6 tumor’s defense strategy, it has also been suggested that
to induce MHC expression in CTVT cells. In addition, IL6 natural regression may be an adaptation to maintain the
induced MHC expression in CTVT in vitro [29] and could viability of the host population [4].
induce MHC expression in combination with IL15 in vivo
[30]. Clinico-pathological Characteristics: In the male dog,
There is convincing evidence that humoral immunity the tumour is usually located on the caudal part of the
plays a role in CTVT progression. Anti bodies recognizing penis, from the crura to bulbis glandis or the area of the
CTVT antigens can be detected in the sera of CTVT glans penis and occasionally on the prepuce [5, 32]. In the
affected animals [6]. Although serum antibody levels did bitch, the neoplasmis usually found in the posterior part
not correlate strongly with tumor volume, they were of the vagina, often at the junction of the vestibule and
undetected able in the serum of puppies with metastatic the vagina. It sometimes surrounds the urethral orifices
CTVT and few cells in CTVT metastases could be labeled and, if it is just within the vagina, it may protrude from the
with anti- CTVT antibodies [15, 17]. vulva [15, 32].
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Fig. 2: Genital and extragenital showing of CTVT from different sources (A) Canine transmissible venereal tumour
(CTVT) a firm, palpable moltinodular mass with hemorrgahic foci is present. (B) Note irregular, cauliflower like
reddish tumour mass on the vagina. (C) Extragenital CTVT. Multilobulated, ulcerated mass. Resembling
cauliflower in the oral cavity of a dog. Mascarenhas et al. [37]. (D) Dog showing tumorous growths on penis and
nearby areas. Source: Behera et al. [36].
The vast majority of cases are sexually transferred, this neoplasm has caused actual Mechanical obstruction
CTVT on the external genitalia of both sexes appear to the flow of urine, or has produced dystocia in whelping
initially as small hyperaemic papules that later progress to females [5, 34].
nodular, papillary multilobulated, caulifower-like or CTVT may also develop in extragenital sites such as
pedunculated proliferations. The tumor size can vary from skin, subcutaneous tissues and around and in the oral
3 to 12 cm in diameter. The mass is firm but friable and the and nasal cavities. Extragenital tumors are well
superficial  part  is   commonly   ulcerated   and  inflamed circumscribed and can measure 2-5 cm [5, 15]. Metastases
[5, 9, 32, 33]. are rare in CTVT, yet they can occur, especially in puppies
During rapid tumour growth, the colour is bright red and immunocompromised dogs. These metastases are
owing to extensive vascularization. The tumour often often considered mechanical extensions of the primary
oozes a serosanguinous, simple haemorrhagic fluid or tumor; however, metastases have been reported in
preputial discharge and eventually becomes ulcerated, inguinal lymph nodes [5, 9, 15]. Brain, liver and eye [12].
with a necrotic appearance [5]. The peculiar odour of the Many of the reported cases of metastasis are actually
neoplastic lesions discharge, which after secondary mechanical extension of the growth or either auto- or
bacterial infection became  particularly  unpleasant  and hetero-transplantation to the skin, cervix, uterus and
the excessive licking of the genitalia [34]. The  continuous fallopian tubes from the tumor on the external genitalia
discharge from the external genitalia, soiling the floor, [36].
carpet and even clothes, is a great nuisance for the owner.
The bloody discharges may be confused  with  oestrus, Histopathology Characteristics: On histopathologic
urethritis  or  cystitis  and  in  the  male,   with   prostatitis. examination, CTVT cells exhibit a round to polyhedral
In older dogs, the differential diagnosis Must also include shape, arranged or grouped in strings, interspersed with
urinary bladder and urethral neoplasms [13, 35]. When delicate conjunctival stroma when stained with
cases become complicated it may cause Phimosis or hematoxylin and eosin. The tumor cells are usually
paraphimosis in the male and few cases are record where arranged radially around blood and lymphatic vessels and
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Fig. 3: Stages of tumour progression. (A) Neoplasia showing high cellularity, mitosis and scarce conjunctive tissue
(Haematoxylin and eosin). (B) Neoplasia in initial regression phase as shown by the presence of TILs
(Haematoxylin and eosin). (C) Final regression stage as seen by tumour parenchyma collapse and substitution
by fibrous tissue (Haematoxylin and eosin) Bar 20 µm. Source: Stockmann et al. [15].
have a high nucleus to cytoplasm ratio with a round Further, CTVT displays histological resemblance to
nucleus  and   chromatin   ranging   from   delicate to canine cutaneous histiocytomas and other round cell
coarse  and  prominent  nucleoli  and  cytoplasmic tumours, thereby presenting great difficulties for
vacuoles  [9,  15,  38].  These  cells  contain  a  large pathologists in their differentiation [40]. So, definitive
amount   of   cytoplasm   that   is   slightly  acidophilic diagnosis could be based on physical examination and
with poorly-defined limits [6, 17]. There is also frequently cytological findings typical of TVT in exfoliated cells
an infiltration of lymphocytes, plasma cells and obtained by swabs, fine needle aspiration or imprints of
macrophages which suggest a role of immune mediated the tumours [41]. This tumour could easily be
control [39]. distinguished from other round cell tumours by a simple
CTVT Undergoes a Predictable Cycle: the initial growth
phase of four to six months (P phase), a stable phase and Cytopathological Characteristics: Cytology must be the
a regression phase (R phase), although not all CTVTs will method of choice for diagnosis of suspected CTVT, since
regress [21]. The progression phase presents as round the technique is simple, cheap, minimally invasive and
cells arranged diffusely, interspersed by delicate painless and, furthermore, produces much less distortion
conjunctival stroma and the frequent presence of mitotic of cell morphology than biopsy samples fixed in formalin
structures. In the initial phase of regression, tumor- [8, 42]. When subjected to Romanovisky staining, both
infiltrating lymphocytes (TILs) appear and are widely genital and extra-genital neoplasias present characteristic
distributed  or  associated  with the conjunctival stroma round cells with distinct cytoplasmic borders. The nuclei
[6, 21]. The final regression phase involves collapse of the are oval or round and centrally-located, with delicate
neoplastic tissue and the frequent presence of apoptotic chromatin and large nucleoli; the cytoplasm is slightly
bodies [6, 15]. CTVTs should be differentiated from acidophilic and contains finely granular, delicate vacuoles
mastocytomas, histiocytomas or malignant lymphomas and cells do not display anisokaryosis, anisocytosis,
[5]. hyperchromasia or nuclear macrokaryosis [43].
algorithm.
Acad. J. Anim. Diseases 4(3): 185-195, 2015
191
Fig. 4: An algorithm used in evaluating and differentiating TVTs from other round cell tumours (a) Round cells with
eccentric nuclei + Cytoplasmic granulation; b. Round cells with centrally placed nuclei + Cytoplasmic
vacuolation; (c) Round cells without cytoplasmic granulation or vacuolation + Bean shaped nucleus; (d) Round
cells without cytoplasmic granulation or vacuolation + Multinucleated giant cells. Source: Thangathurai et al.
[41].
Cytological    samples      of      CTVT are   generally such as lymphocytes, plasma cells, macrophages and
multicellular and contain round or oval cells that vary neutrophils are observed regardless of the stage of
between14 and 30 µ in diameter, with well-delimited neoplastic development [15].
cytoplasmic borders. The nucleus, round or oval, is
frequently eccentric, of variable size, with rough and Diagnosis of CTVT: Diagnosis is based on the
granular chromatin and with one or two prominent environmental history, clinical and cytological findings.
nucleoli and The nucleus to cytoplasm ratio is relatively Biopsy for histological examination is the most reliable
high [8]. method for diagnosis. Many of the diagnostic difficulties
CTVT tumor based on the predominant cell type as previously faced by pathologists have, however, been
lymphoid, plasmacytoid or mixed. The lymphoid type of eased by the introduction of novel techniques such as
tumor predominantly includes cells with a rounded immunohistochemistry and/or immunocytochemistry and
morphology, scant and finely granular cytoplasm, the molecular biology [5, 46].
presence of vacuoles and round nuclei with coarse
chromatin and the presence of one or two evident nucleoli Hemato-biochemical Diagnosis of CTVT: Studies using
[44]. In plasmacytoid tumors, most cells have an ovoid Hemato-biochemical observations in the mongrel dog
morphology, a smaller relative nucleus: cytoplasm ratio demonstrated that this neoplasm shows markedly
and eccentrically-located nuclei, whereas the mixed type elevated with neutrophilia, lymphopenia and
of tumor exhibits mixed cellularity [45]. thrombocytopenia. Serum chemistry was indicative of
Many times the cellular aspect can vary between the hypoproteinemia, hypoalbuminemia, hypoglobulinemia
primary tumor and the metastasis or can be atypical in with higher levels of blood urea nitrogen and creatinine.
cases of old and are indicative of proliferation of tumor Increased activities of alanine aminotransferase and
cells [15, 45]. Apoptotic bodies of are also observed by alkaline phosphatase were also observed probably due to
cytological exam and are present in higher quantities in metastasis to these organs affecting the organ function
CTVT in the regression phase [38]. Inflammatory cells [36].
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Fig. 5: Cytological samples of transmissible venereal tumor of different cytomorphological types: (A) lymphocytic
pattern (Predominance of round cells, scarce cytoplasm and high nucleus:cytoplasm ratio); (B) plasmacytic
pattern (Predominance of ovoid cells, ample cytoplasm and eccentric nucleus); (C) mixed pattern (Presence of
both morphological types without predominance of either. Giemsa, bar = 20µm, Source: Amaral et al. [8].
Free radicals are highly reactive molecules produced Immunohistochemical      Diagnosis        of     CTVT:
during normal metabolism in the body, or after exposure Most canine round cell tumours have been
to environmental factors, which are kept in equilibrium by immunocharacterized using several tumour markers
the body through endogenous antioxidant defense making  it  easy  for  accurate   diagnosis  and
mechanisms (Comprising of superoxide dismutase (SOD), classification   [37].   Although   CTVT  has  been
catalase (CAT), glutathione peroxidase, glutathione subjected  to   immunohistochemical   studies  with
reductase and glutathione (GSH) etc. If this balance is several tumour markers, its origin and the
disturbed, it may result in oxidative stress, leading to immunophenotype still remain uncertain. However,
enhanced lipid peroxidation, DNA strand breaks and immunohistochemical studies with a panel of several
protein damage [47]. The role of oxidative stress in antibodies have managed to rule out some of the early
carcinogenesis has been delineated in dogs with suggestions [6].
lymphoma [48]. CTVT in bitches [49]. And canine CTVT cells are negative for keratins, -smooth
mammary tumors [50]. muscle actin, desmin, CD3, immunoglobulins G and M, -
Hemato-biochemical study by Behera et al. [36] light chains and -light chains and this means that an
revealed a marked increase in the level of lipid epithelial, smooth muscle and T and B lymphocyte origin
peroxidation (LPO, 3.84 çmol MDA/mg Hb; control: 0.94), can be ruled out [4, 51].
a  decreased   level   of   reduced   glutathione   (GSH,  0.76 Antibodies against  CD3,  surface immunoglobulins
ìmol/mg Hb; control: 1.14), reduced activities of G  and   M, -light   chains   and -light  chains are
superoxide dismutase (SOD, 0.73 Units/mg Hb; control: useful for differentiating CTVT from lymphomas and
1.29) and catalase (CAT, 74.37 Units/mg Hb; control: plasma  cell  tumours  [44]. Lysozyme and alpha-
132.25). These alterations in oxidant-antioxidant status antitrypsin   (AAT)   have  been  considered  good
might be due to direct injury by tumor cells or markers  for  benign  and  malignant  histiocytes  and
inflammation and/or necrosis which needs further these antigens are not expressed by other mesenchymal
validation in similar types of cases. cells [5, 15].
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The phenotypic origin of CTVT is not yet clear, but REFERENCES
the expression of ACM1, lysozyme and AAT suggest a
histiocytic origin because these antigens are not
expressed by other mesenchymal round cells, except
those of hystiocytic origin [6, 37]. 
Molecular Diagnosis of CTVT: Molecular biology can
also be useful in the diagnosis of canine TVT. The c-myc
oncogene is rearranged in this tumour by insertion of a
transposable sequence, known as the long interspersed
element (LINE), 5’ to the first exon [21]. This genomic
rearrangement has been identified in a large set of globally
distributed CTVT tumors, but not in any other canine
tissue and is now considered diagnostic evidence for
CTVT [4, 9, 10, 15]. It is possible that this rearrangement
was present in the germ line of the CTVT founder, that it
occurred somatically during the development of the
founding CTVT tumor or that it occurred somatically in a
CTVT clone that has subsequently achieved global
distribution [17].
Several treatments including surgery, radiotherapy
and chemotherapy have been used to treat CTVTs.
Surgery has been used extensively to treat small, localised
TVTs, although the recurrence rate can be as high as
50–68% in cases of large invasive tumours. Chemotherapy
using antimitotic agents such as vincristine, cyclo-
phosphamide, methotrexate, vinblastine and doxorubicin
is the most effective TVT treatment [1,5].
CONCLUSION
CTVT is the most prevalent  neoplasia  of  the
external genitalia of the dog in tropical and sub-tropical
areas. The most frequent owner’s complaint is the
hemorrhagic discharge. Diagnosis is based on typical
physical, cytological, histochemical and molecular
findings.
Therefore, based on these facts, the following
recommendations are forwarded; more study should be
done on hematological and biochemical nature of CTVT,
role of the tumour stroma (Fibroblasts, vessels and
extracellular matrix components) in the progression of
CTVT and also analysis of the temporal expression of
extracellular matrix components like tenascin, hyaluronan
and versican that play an important role in tumour
progression in CTVT. And dog licensing laws, controlling
the pool of potentially infected, owner less dogs roaming
wild, will control the incidence of the disease.
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